...an MAA to EMA by year-end and a BLA to FDA in mid-2021. Delay for Lipocine’s Tlando Lipocine Inc....
...Brand), Farxiga (Brand), BMS-512148 (Former compound #), dapagliflozin (Generic), Forxiga (Other) Tlando, testosterone undecanoate (LPCN 1021) AstraZeneca plc Lipocine Inc. U.S...

...Ildong Pharmaceutical Co. Ltd. (KRX:000230) Ublituximab Treat chronic lymphocytic leukemia (CLL) Phase III data 2H19 Lipocine Inc....

...new guidance at its R&D day Tuesday. Fresh review for Lipocine’s Tlando after FDA setback Lipocine Inc....
...Nov. 9. Elizabeth S. Eaton, Staff Writer FS118 Humira, adalimumab (D2E7) Tlando, testosterone undecanoate (LPCN 1021) AbbVie Inc. F-star Biotechnology Ltd. Ipsen Group Lipocine Inc. Merck...

...Co. Ltd. (Tokyo:4151) / Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Burosumab X-linked hypophosphatemia (XLH) PDUFA date 4/17/18 Lipocine Inc....

...period after Lipocine submitted additional data for the candidate (see BioCentury, Dec. 1, 2017 ). Lipocine...
...letter in 2016 identifying problems with its proposed dose titration scheme for clinical practice, which Lipocine...
...is an oral ester prodrug of testosterone that uses Lipocine's Lip'ral promicellar drug delivery technology. Lipocine...

...after Lipocine submitted additional data for the candidate (see BioCentury Extra, Nov. 17, 2017) . Lipocine...
...letter in 2016 identifying problems with its proposed dose titration scheme for clinical practice, which Lipocine...
...is an oral ester prodrug of testosterone that uses Lipocine's Lip'ral promicellar drug delivery technology. Lipocine...

...CTCL) in patients who have received at least one prior systemic therapy PDUFA date 6/4/18 Lipocine Inc....

...testosterone undecanoate (LPCN 1021) to treat hypogonadism. The candidate’s new PDUFA date is May 8. Lipocine...
...time for analysis of data submitted by the company as an amendment to Tlando's NDA. Lipocine...
...is an oral ester prodrug of testosterone that uses Lipocine's Lip'ral promicellar drug delivery technology. Lipocine Inc....

...undecanoate (LPCN 1021) to treat hypogonadism. The candidate’s new PDUFA date is May 8, 2018. Lipocine...
...time for analysis of data submitted by the company as an amendment to Tlando's NDA. Lipocine...
...Lipocine's Lip'ral promicellar drug delivery technology. Lipocine slipped $0.22 to $3.63 on Friday. Jaime De Leon LPCN 1021 Tlando Lipocine Inc. testosterone...

...Recro Pharma Inc. (NASDAQ:REPH) named Jyrki Mattila EVP of business development. He was CBO at Lipocine Inc....